Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review
80
Zitationen
11
Autoren
2019
Jahr
Abstract
ESA-treated patients undergoing dialysis incurred lower costs, lower HRU, and had better HRQoL relative to ESA-untreated patients. However, treatment to higher Hb targets led to modest HRQoL improvements compared to lower Hb targets.
Ähnliche Arbeiten
The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
1996 · 22.281 Zit.
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
2017 · 4.816 Zit.
Anemia of Chronic Disease
2005 · 3.726 Zit.
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 · 2.744 Zit.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 · 2.190 Zit.
Autoren
Institutionen
- New York Hospital Queens(US)
- Pontifícia Universidade Católica do Paraná(BR)
- The George Institute for Global Health(AU)
- Baylor College of Medicine(US)
- Renal Associates P. A.(US)
- Akebia Therapeutics (United States)(US)
- Pharmaceutical Product Development (United States)(US)
- Otsuka (United States)(US)
- Otsuka Pharmaceutical (Spain)(ES)